[go: up one dir, main page]

WO1993024117A3 - Medicaments pour le traitement de l'anxiete - Google Patents

Medicaments pour le traitement de l'anxiete Download PDF

Info

Publication number
WO1993024117A3
WO1993024117A3 PCT/GB1993/001013 GB9301013W WO9324117A3 WO 1993024117 A3 WO1993024117 A3 WO 1993024117A3 GB 9301013 W GB9301013 W GB 9301013W WO 9324117 A3 WO9324117 A3 WO 9324117A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
anxiety
medicaments
prophylaxis
mammals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1993/001013
Other languages
English (en)
Other versions
WO1993024117A2 (fr
Inventor
Gordon Smith Baxter
Guy Anthony Kennett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929211082A external-priority patent/GB9211082D0/en
Priority claimed from GB929214399A external-priority patent/GB9214399D0/en
Priority claimed from GB929219356A external-priority patent/GB9219356D0/en
Priority claimed from GB929227045A external-priority patent/GB9227045D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to JP6500284A priority Critical patent/JPH07507290A/ja
Priority to US08/341,577 priority patent/US5763459A/en
Priority to EP93910220A priority patent/EP0641198A1/fr
Publication of WO1993024117A2 publication Critical patent/WO1993024117A2/fr
Publication of WO1993024117A3 publication Critical patent/WO1993024117A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un procédé de traitement et/ou de prophylaxie de l'anxiété chez les mammifères dont l'homme. Ce procédé consiste à administrer au mammifère ayant besoin de ce traitement et/ou de cette prophylaxie, une quantité efficace et/ou prophylactique d'un antagoniste des récepteurs 5-HT¿4?
PCT/GB1993/001013 1992-05-23 1993-05-18 Medicaments pour le traitement de l'anxiete Ceased WO1993024117A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP6500284A JPH07507290A (ja) 1992-05-23 1993-05-18 不安症の治療のための医薬
US08/341,577 US5763459A (en) 1992-05-23 1993-05-18 Medicaments for the treatment of anxiety
EP93910220A EP0641198A1 (fr) 1992-05-23 1993-05-18 Medicaments pour le traitement de l'anxiete

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB9211082.4 1992-05-23
GB929211082A GB9211082D0 (en) 1992-05-23 1992-05-23 Pharmaceuticals
GB929214399A GB9214399D0 (en) 1992-07-07 1992-07-07 Pharmaceuticals
GB9214399.9 1992-07-07
GB9219356.4 1992-09-12
GB929219356A GB9219356D0 (en) 1992-09-12 1992-09-12 Pharmaceuticals
GB9227045.3 1992-12-29
GB929227045A GB9227045D0 (en) 1992-12-29 1992-12-29 Pharmaceuticals

Publications (2)

Publication Number Publication Date
WO1993024117A2 WO1993024117A2 (fr) 1993-12-09
WO1993024117A3 true WO1993024117A3 (fr) 1994-04-14

Family

ID=27450876

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1993/001013 Ceased WO1993024117A2 (fr) 1992-05-23 1993-05-18 Medicaments pour le traitement de l'anxiete

Country Status (6)

Country Link
US (1) US5763459A (fr)
EP (1) EP0641198A1 (fr)
JP (1) JPH07507290A (fr)
AU (1) AU4081393A (fr)
MX (1) MX9302985A (fr)
WO (1) WO1993024117A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
WO1994008965A1 (fr) * 1992-10-16 1994-04-28 Smithkline Beecham Plc Esters/amides n-alkylpiperidinyl-4-methyl carboxyliques des systemes de cycles condenses en tant qu'inhibiteurs de recepteurs 5-ht4
US5654320A (en) * 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
US6069152A (en) * 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
GB0905641D0 (en) * 2009-04-01 2009-05-13 Serodus As Compounds

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0076530A2 (fr) * 1981-10-01 1983-04-13 Janssen Pharmaceutica N.V. Dérivés de la N-(3-hydroxy-4-piperidinyl)benzamide
EP0229444A2 (fr) * 1985-07-24 1987-07-22 Glaxo Group Limited Médicaments pour le traitement de l'anxiété
EP0278173A2 (fr) * 1986-12-17 1988-08-17 Glaxo Group Limited Emploi de dérivés hétérocycliques pour le traitement de la dépression
EP0309423A2 (fr) * 1987-09-23 1989-03-29 BOEHRINGER INGELHEIM ITALIA S.p.A. Dérivés de l'acide benzimidazoline-2-oxo-1-carboxylique utiles commes antagonistes des 5-HT récepteurs
WO1990012569A1 (fr) * 1989-04-21 1990-11-01 Sandoz Ag Application therapeutique d'antagonistes du recepteur 5-ht¿3?
EP0501322A1 (fr) * 1991-02-25 1992-09-02 Glaxo Group Limited Esters pipéridimylmethyl substitués d'acide indole-3-carbonyligne
EP0505322A1 (fr) * 1991-03-22 1992-09-23 Sandoz Ltd. Aminoguanidines
FR2674853A1 (fr) * 1991-04-03 1992-10-09 Synthelabo Derives de piperidinylguanidine, leur preparation et leur application en therapeutique.
WO1993002677A1 (fr) * 1991-08-03 1993-02-18 Smithkline Beecham Plc Antagonistes du recepteur 5-ht4
WO1993003725A1 (fr) * 1991-08-20 1993-03-04 Smithkline Beecham Plc Antagonistes du recepteur 5-ht4
WO1993005038A1 (fr) * 1991-09-12 1993-03-18 Smithkline Beecham Plc Antagonistes de recepteurs 5-hydroxytriptamine 4
WO1993005040A1 (fr) * 1991-09-12 1993-03-18 Smithkline Beecham Plc Composes azacycliques utilises comme antagonistes du recepteur 5-ht¿4?
WO1993008187A1 (fr) * 1991-10-24 1993-04-29 Smithkline Beecham Plc Imidazopyridines et indolizines en tant qu'antagonistes de 5-ht¿4?
WO1993014745A1 (fr) * 1992-01-23 1993-08-05 Smithkline Beecham Plc Utilisation d'antagonistes de recepteur de 5-ht4 comme medicaments pour traiter la migraine
WO1993016072A1 (fr) * 1992-02-06 1993-08-19 Smithkline Beecham Plc Derives de benzopyrane, de benzothiopyrane et de coumarone utilises comme antagonistes du recepteur 5-ht4

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0076530A2 (fr) * 1981-10-01 1983-04-13 Janssen Pharmaceutica N.V. Dérivés de la N-(3-hydroxy-4-piperidinyl)benzamide
EP0229444A2 (fr) * 1985-07-24 1987-07-22 Glaxo Group Limited Médicaments pour le traitement de l'anxiété
EP0278173A2 (fr) * 1986-12-17 1988-08-17 Glaxo Group Limited Emploi de dérivés hétérocycliques pour le traitement de la dépression
EP0309423A2 (fr) * 1987-09-23 1989-03-29 BOEHRINGER INGELHEIM ITALIA S.p.A. Dérivés de l'acide benzimidazoline-2-oxo-1-carboxylique utiles commes antagonistes des 5-HT récepteurs
WO1990012569A1 (fr) * 1989-04-21 1990-11-01 Sandoz Ag Application therapeutique d'antagonistes du recepteur 5-ht¿3?
EP0501322A1 (fr) * 1991-02-25 1992-09-02 Glaxo Group Limited Esters pipéridimylmethyl substitués d'acide indole-3-carbonyligne
EP0505322A1 (fr) * 1991-03-22 1992-09-23 Sandoz Ltd. Aminoguanidines
FR2674853A1 (fr) * 1991-04-03 1992-10-09 Synthelabo Derives de piperidinylguanidine, leur preparation et leur application en therapeutique.
WO1993002677A1 (fr) * 1991-08-03 1993-02-18 Smithkline Beecham Plc Antagonistes du recepteur 5-ht4
WO1993003725A1 (fr) * 1991-08-20 1993-03-04 Smithkline Beecham Plc Antagonistes du recepteur 5-ht4
WO1993005038A1 (fr) * 1991-09-12 1993-03-18 Smithkline Beecham Plc Antagonistes de recepteurs 5-hydroxytriptamine 4
WO1993005040A1 (fr) * 1991-09-12 1993-03-18 Smithkline Beecham Plc Composes azacycliques utilises comme antagonistes du recepteur 5-ht¿4?
WO1993008187A1 (fr) * 1991-10-24 1993-04-29 Smithkline Beecham Plc Imidazopyridines et indolizines en tant qu'antagonistes de 5-ht¿4?
WO1993014745A1 (fr) * 1992-01-23 1993-08-05 Smithkline Beecham Plc Utilisation d'antagonistes de recepteur de 5-ht4 comme medicaments pour traiter la migraine
WO1993016072A1 (fr) * 1992-02-06 1993-08-19 Smithkline Beecham Plc Derives de benzopyrane, de benzothiopyrane et de coumarone utilises comme antagonistes du recepteur 5-ht4

Also Published As

Publication number Publication date
US5763459A (en) 1998-06-09
AU4081393A (en) 1993-12-30
EP0641198A1 (fr) 1995-03-08
JPH07507290A (ja) 1995-08-10
MX9302985A (es) 1993-11-01
WO1993024117A2 (fr) 1993-12-09

Similar Documents

Publication Publication Date Title
ZA961150B (en) Substituted isoxazoles for the treatment of inflammation.
AP9801272A0 (en) Use of an antagonist of ppar-alpha and ppr-gamma for the treatment of syndrom X.
BG100960A (bg) Дозирани форми с контролирано освобождаване на азитромицин
ZA949418B (en) Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
EP0715855A3 (fr) Recepteurs antagonistes NK-1 et recepteurs antagonistes 5HT3 pour le traitement des vomissements
GR3036347T3 (en) Compounds useful for treating allergic and inflammatory diseases.
EP0634930A4 (en) Compounds useful for treating allergic and inflammatory diseases.
MY115310A (en) Substance p antagonists for the treatment of emesis
HUP9902889A3 (en) The use of 3-phenyl-4-(4-methylsulphonyl)-phenyl-2-(5h)-furanone for producing anti inflammatory medicaments and such medicaments
WO1997009976A3 (fr) Procede d'attenuation de troubles dus a des neurotoxines par des chelatants du zinc
HU9503625D0 (en) Use of p antagonist for producing pharmaceutical compositions for treating acne, rosacea and/or pubic arythema
AU2784792A (en) Human monoclonal antibodies to the cd4-binding domain of hiv, uses thereof and synergistic neutralization of hiv
WO1993024117A3 (fr) Medicaments pour le traitement de l'anxiete
AU4090289A (en) Method for the treatment of wool
EP0325129A3 (en) Disubstituted pyridines
AU4726797A (en) Prophylactic/remedial agent
AU2806692A (en) Medicament for the treatment of anxiety
AU6494690A (en) Method for the prevention and treatment of bovine mastitis
WO1991016045A3 (fr) Utilisation d'antagonistes de recepteurs 5-ht4 dans le traitement d'arythmies et d'ictus
AU8634291A (en) Process and device for the manufacture of high-pressure laminates
WO1994000113A3 (fr) Medicaments renfermant des antagonistes du recepteur de 5-ht¿4?
EP0345948A3 (fr) Utilisation de 5-HT1A agonistes pour l'obtention d'un médicament protégeant contre les conséquences d'une attaque ischémique
IL116826A (en) Use of 3,4-diphenyl chromans for the preparation of pharmaceutical compositions for treatment or prophylaxis of obesity
GB8927980D0 (en) Pharmaceuticals
ZA949564B (en) Method for treating constipation using dimeticone.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1993910220

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 08341577

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1993910220

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1993910220

Country of ref document: EP